Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.

< BACK TO ARCHIVE


Papers: 27 Mar 2021 - 2 Apr 2021


Human Studies, Pharmacology/Drug Development


2021 Mar 30


J Headache Pain


http://www.ncbi.nlm.nih.gov/pubmed/33781209?dopt=Abstract


22


1

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.

Authors

Safety and tolerability of eptinezumab in patients with migraine: a pooled analysis of 5 clinical trials.
Smith TR, Spierings ELH, Cady R, Hirman J, Schaeffler B, Shen V, Sperling B, Brevig T, Josiassen M K, Brunner E, Honeywell L, Mehta L
J Headache Pain. 2021 Mar 30; 22(1):16.
PMID: 33781209.

Abstract

The humanized anti-CGRP monoclonal antibody eptinezumab has been evaluated in five large-scale clinical trials conducted in patients with migraine. This integrated analysis was conducted to evaluate the comprehensive safety and tolerability of eptinezumab in patients with migraine across these studies.
Read This Paper